By otakuyassine3@gmail.com 
ExodusPoint Capital Management LP lowered its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX – Free Report) by 38.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,635 shares of the medical device company’s stock after selling 18,081 shares during the period. ExodusPoint Capital Management LP owned about 0.07% of Orthofix Medical worth $500,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Trexquant Investment LP lifted its holdings in shares of Orthofix Medical by 75.3% in the fourth quarter. Trexquant Investment LP now owns 55,680 shares of the medical device company’s stock worth $972,000 after acquiring an additional 23,912 shares during the last quarter. Geode Capital Management LLC lifted its stake in Orthofix Medical by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 841,637 shares of the medical device company’s stock valued at $14,699,000 after purchasing an additional 2,448 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Orthofix Medical in the 4th quarter valued at approximately $1,286,000. JPMorgan Chase & Co. boosted its position in Orthofix Medical by 244.1% in the fourth quarter. JPMorgan Chase & Co. now owns 290,351 shares of the medical device company’s stock valued at $5,070,000 after buying an additional 205,972 shares in the last quarter. Finally, Emerald Advisers LLC grew its stake in shares of Orthofix Medical by 12.2% during the fourth quarter. Emerald Advisers LLC now owns 822,377 shares of the medical device company’s stock worth $14,359,000 after buying an additional 89,717 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
OFIX has been the subject of a number of research reports. Roth Mkm reiterated a “buy” rating and issued a $22.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. Canaccord Genuity Group reiterated a “buy” rating and issued a $24.00 target price on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.
Get Our Latest Research Report on Orthofix Medical
Orthofix Medical Stock Down 1.8 %
Shares of OFIX opened at $13.67 on Friday. The stock’s 50-day moving average price is $16.77 and its two-hundred day moving average price is $17.23. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a market capitalization of $533.43 million, a PE ratio of -4.37 and a beta of 0.99. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.
Insider Buying and Selling
In other Orthofix Medical news, insider Lucas Vitale sold 4,287 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $16.60, for a total transaction of $71,164.20. Following the completion of the transaction, the insider now owns 135,317 shares in the company, valued at approximately $2,246,262.20. This trade represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Julie Andrews sold 4,655 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,511 shares of company stock valued at $335,827 over the last ninety days. 2.60% of the stock is owned by company insiders.
Orthofix Medical Profile
Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Featured Articles
Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix Medical Inc. (NASDAQ:OFIX – Free Report).
Receive News & Ratings for Orthofix Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Orthofix Medical and related companies with MarketBeat.com’s FREE daily email newsletter.